MAPK14 and congenital rubella syndrome: <h4>Background and aim</h4>POLB 001 is an oral p38 mitogen-activated protein kinase (MAPK) inhibitor in development for the prevention of cancer immunotherapy-induced cytokine release syndrome (CRS).